SCHEDULE 13G/A: Knight Therapeutics Boosts Stake in Synergy CHC Corp. to 19.90%

Knight Therapeutics Inc. has reported an increased beneficial ownership stake of 19.90% in Synergy CHC Corp., including shares held directly and through warrants.

Summary

• Knight Therapeutics Inc. (Reporting Person) has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Synergy CHC Corp. (Issuer).
• The aggregate amount beneficially owned by Knight Therapeutics Inc. is 1,911,414 shares of common stock.
• This represents 19.90% of Synergy CHC Corp.'s common stock class.
• The ownership includes 1,482,844 shares held directly by Knight Therapeutics Inc. and 428,570 shares issuable upon the exercise of pre-funded common stock purchase warrants.
• These warrants are held indirectly by Knight Therapeutics International S.A., a wholly-owned subsidiary of the Reporting Person, with an exercise price of $0.00001 per share.
• The percentage of beneficial ownership is calculated based on a total of 9,442,680 shares, comprising 9,014,110 shares outstanding as of May 13, 2025, and the 428,570 warrant shares.
• Knight Therapeutics Inc. certifies that the securities were not acquired for the purpose of changing or influencing the control of Synergy CHC Corp., other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of a significant passive stake. The increased stake by an institutional investor can be seen as a vote of confidence, but the document itself does not contain performance data.

Positives

• A significant institutional investor, Knight Therapeutics Inc., has increased its stake, potentially indicating confidence in Synergy CHC Corp.'s long-term value.
• The ownership includes warrants with a very low exercise price ($0.00001 per share), suggesting a favorable entry point for Knight Therapeutics.

Risks

• The beneficial ownership is subject to a post-exercise limitation of 19.90%, which could cap Knight Therapeutics' immediate influence or further accumulation without triggering additional reporting requirements.
• The value of the warrant shares is dependent on the future performance and market price of Synergy CHC Corp.'s common stock.

Future Outlook

The document is a beneficial ownership filing and does not contain forward-looking statements or guidance from Synergy CHC Corp. or Knight Therapeutics Inc. regarding future performance or strategic direction, beyond the passive investment intent.

Management Comments

• "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc.

Industry Context

This filing indicates a significant stake by a Canadian pharmaceutical company, Knight Therapeutics, in Synergy CHC Corp. While the specific industry of Synergy CHC Corp. is not detailed, the investment by Knight Therapeutics suggests a potential alignment or interest in the consumer health or pharmaceutical sector. Such passive investments by larger entities in smaller companies are common and can signal strategic interest or simply a belief in the target company's long-term value.

Comparison to Industry Standards

• This document is a beneficial ownership filing (Schedule 13G) and does not provide financial or operational results for comparison to industry standards. It solely reports an ownership stake. Therefore, specific comparable companies, projects, or results are not applicable for assessment within this document's scope.

Stakeholder Impact

• Shareholders: Increased institutional ownership might be viewed positively, potentially signaling confidence and stability.
• Management: The certification states no intent to influence control, suggesting continued operational autonomy for Synergy CHC Corp.'s management.

Next Steps

• Synergy CHC Corp. will continue its operations.
• Knight Therapeutics Inc. will continue to hold its stake in Synergy CHC Corp.
• Further Schedule 13D/G filings would be required if Knight Therapeutics' ownership percentage changes significantly or if its investment intent shifts from passive to active.

Key Dates

Recommendation

Keywords

Synergy CHC Corp., Knight Therapeutics Inc., Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Institutional Investor, Equity Stake